Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Wave Life Sciences Ltd. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

  • $92.2 Billion
  • Q3 2024

A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 41,620 shares of WVE stock, worth $561,037. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,620
Previous 45,557 8.64%
Holding current value
$561,037
Previous $227,000 50.22%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
SELL
$5.12 - $9.01 $20,157 - $35,472
-3,937 Reduced 8.64%
41,620 $341,000
Q2 2024

Aug 12, 2024
BUY
$4.38 - $6.48 $199,539 - $295,209
45,557 New
45,557 $227,000
Q2 2020

Aug 06, 2020
SELL
$7.44 - $11.29 $31,753 - $48,185
-4,268 Closed
0 $0
Q1 2020

May 11, 2020
BUY
$6.94 - $14.22 $7,245 - $14,845
1,044 Added 32.38%
4,268 $40,000
Q4 2019

Feb 05, 2020
SELL
$7.99 - $37.6 $10,474 - $49,293
-1,311 Reduced 28.91%
3,224 $25,000
Q3 2019

Nov 12, 2019
BUY
$19.17 - $27.4 $17,655 - $25,235
921 Added 25.48%
4,535 $93,000
Q2 2019

Aug 08, 2019
BUY
$22.93 - $42.84 $13,047 - $24,375
569 Added 18.69%
3,614 $94,000
Q1 2019

Apr 26, 2019
BUY
$32.69 - $47.91 $15,102 - $22,134
462 Added 17.89%
3,045 $118,000
Q4 2018

Feb 08, 2019
SELL
$37.1 - $50.11 $2,188 - $2,956
-59 Reduced 2.23%
2,583 $101,000
Q3 2018

Nov 13, 2018
BUY
$36.35 - $55.2 $96,036 - $145,838
2,642 New
2,642 $132,000

Others Institutions Holding WVE

# of Institutions
164
Shares Held
117M
Call Options Held
148K
Put Options Held
109K
View Full List

About Wave Life Sciences Ltd.

WVE Quotes by TradingView
  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.17B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email